vs
Side-by-side financial comparison of New Fortress Energy Inc. (NFE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -259.7%, a 261.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -7.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -26.8%).
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NFE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $326.2M | $177.4M |
| Net Profit | $-847.1M | $2.9M |
| Gross Margin | 35.5% | — |
| Operating Margin | -193.0% | 3.9% |
| Net Margin | -259.7% | 1.6% |
| Revenue YoY | -7.0% | 5.0% |
| Net Profit YoY | -277.4% | — |
| EPS (diluted) | $-3.03 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $326.2M | $196.9M | ||
| Q3 25 | $240.3M | $179.5M | ||
| Q2 25 | $228.1M | $181.1M | ||
| Q1 25 | $384.9M | $168.9M | ||
| Q4 24 | $350.7M | $187.3M | ||
| Q3 24 | $446.0M | $168.6M | ||
| Q2 24 | $291.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-847.1M | — | ||
| Q3 25 | $-263.0M | $5.4M | ||
| Q2 25 | $-546.5M | $-4.8M | ||
| Q1 25 | $-175.4M | $4.8M | ||
| Q4 24 | $-224.4M | — | ||
| Q3 24 | $9.3M | $-143.5M | ||
| Q2 24 | $-88.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 35.5% | 79.5% | ||
| Q3 25 | 18.1% | 80.9% | ||
| Q2 25 | 8.4% | 77.4% | ||
| Q1 25 | 21.4% | 79.7% | ||
| Q4 24 | 17.6% | 78.7% | ||
| Q3 24 | 27.1% | 76.9% | ||
| Q2 24 | 23.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -193.0% | 1.2% | ||
| Q3 25 | -37.4% | 3.5% | ||
| Q2 25 | -170.3% | 4.7% | ||
| Q1 25 | -3.3% | 1.2% | ||
| Q4 24 | 65.0% | 13.2% | ||
| Q3 24 | 17.8% | -82.8% | ||
| Q2 24 | 12.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -259.7% | — | ||
| Q3 25 | -109.4% | 3.0% | ||
| Q2 25 | -239.6% | -2.7% | ||
| Q1 25 | -45.6% | 2.8% | ||
| Q4 24 | -64.0% | — | ||
| Q3 24 | 2.1% | -85.1% | ||
| Q2 24 | -30.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-3.03 | $0.05 | ||
| Q3 25 | $-0.96 | $0.12 | ||
| Q2 25 | $-1.99 | $-0.11 | ||
| Q1 25 | $-0.65 | $0.10 | ||
| Q4 24 | $-1.10 | $0.38 | ||
| Q3 24 | $0.03 | $-3.11 | ||
| Q2 24 | $-0.42 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.5M | $144.3M |
| Total DebtLower is stronger | $8.2B | — |
| Stockholders' EquityBook value | $182.6M | $653.9M |
| Total Assets | $10.6B | $1.2B |
| Debt / EquityLower = less leverage | 44.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $226.5M | $238.4M | ||
| Q3 25 | $145.2M | $246.3M | ||
| Q2 25 | $551.1M | $445.9M | ||
| Q1 25 | $447.9M | $493.6M | ||
| Q4 24 | $492.9M | $484.6M | ||
| Q3 24 | $90.8M | $453.8M | ||
| Q2 24 | $133.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $8.2B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $8.9B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $182.6M | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.3B | $757.8M | ||
| Q1 25 | $1.8B | $798.5M | ||
| Q4 24 | $1.9B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.6B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $10.6B | $1.3B | ||
| Q3 25 | $12.0B | $1.3B | ||
| Q2 25 | $12.0B | $1.5B | ||
| Q1 25 | $13.1B | $1.6B | ||
| Q4 24 | $12.9B | $1.6B | ||
| Q3 24 | $12.0B | $1.5B | ||
| Q2 24 | $11.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 44.78× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 4.74× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-76.2M | — |
| Free Cash FlowOCF − Capex | $-134.8M | — |
| FCF MarginFCF / Revenue | -41.3% | — |
| Capex IntensityCapex / Revenue | 18.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-76.2M | $43.7M | ||
| Q3 25 | $-171.0M | $60.8M | ||
| Q2 25 | $-329.0M | $12.0M | ||
| Q1 25 | $-7.2M | $35.5M | ||
| Q4 24 | $445.3M | $33.1M | ||
| Q3 24 | $-20.0M | $53.9M | ||
| Q2 24 | $113.9M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-134.8M | $43.5M | ||
| Q3 25 | $-231.6M | $57.0M | ||
| Q2 25 | $-726.7M | $9.3M | ||
| Q1 25 | $-262.3M | $26.9M | ||
| Q4 24 | $-210.3M | $31.0M | ||
| Q3 24 | $-367.0M | $49.8M | ||
| Q2 24 | $-493.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -41.3% | 22.1% | ||
| Q3 25 | -96.4% | 31.7% | ||
| Q2 25 | -318.6% | 5.1% | ||
| Q1 25 | -68.2% | 15.9% | ||
| Q4 24 | -60.0% | 16.6% | ||
| Q3 24 | -82.3% | 29.6% | ||
| Q2 24 | -169.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 18.0% | 0.1% | ||
| Q3 25 | 25.2% | 2.2% | ||
| Q2 25 | 174.4% | 1.5% | ||
| Q1 25 | 66.3% | 5.1% | ||
| Q4 24 | 187.0% | 1.1% | ||
| Q3 24 | 77.8% | 2.4% | ||
| Q2 24 | 208.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.15× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NFE
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
